Moderna MRNA
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on MRNA
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on MRNA.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
MRNA at a glance
MRNA is priced at $254.19 right now, up 5.27% on the session. That puts its market value at $101.48B, 202nd largest among the 3753 stocks we cover.
The 52-week range is $22.28 to $267.50. Today's price is about 95% of the way from the low to the high. Holders are ahead 935.8% over twelve months, and up 325.0% across the last three months.
On the chart it holds above both the 50-day ($191.85) and 200-day ($91.47) moving averages; RSI is 64, and the last 30 sessions moved at roughly 101% annualized volatility.
In the quarter ended Jun 2026 the company brought in $143.00M of revenue, up 4.4% from a year earlier, and a net loss of $782.00M.
13 analysts follow the stock and the average call is "hold". The mean target, $146.67, sits 42.3% under where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 3 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
13 analysts, consensus Hold.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
MRNA is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $146.67, 42.3% below today’s price, with a consensus rating of Hold. Morningstar’s fair value model puts the stock at $163.00, so shares trade 55.9% above that estimate. On earnings multiple, it sits in the 1st percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Moderna: the business
Moderna develops vaccines and treatments based on mRNA technology, and became known for its COVID-19 vaccine.
What tends to move it. Declining COVID vaccine sales, cost cuts and the outcome of flu and cancer vaccine trials shape the stock, and it burns cash.
Where the case gets weaker. COVID vaccine revenue keeps shrinking, and if flu or cancer vaccine trials disappoint, there's no clear next product to replace it while the company is still burning cash, which would force either deeper cuts or new financing on worse terms.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +13.0% | Bullish |
| Price vs 50-day average | +32.5% | Bullish |
| Price vs 200-day average | +177.9% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 63.7 | Bullish |
| MACD (12,26,9) | 14.41 | Bullish |
| Bollinger band position | 93% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How MRNA ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
MRNA stock: common questions
How is Moderna stock doing today?
$254.19 is the latest print for MRNA, a move of +5.27% against yesterday's close of $241.46. Today's low and high so far: $237.86 and $267.50.
How big is Moderna?
Equity value comes to $101.48B at the current price. By that measure it is number 202 of the 3753 names in our coverage.
How far is MRNA from its yearly high?
The year's floor is $22.28 and the ceiling $267.50. Shares are 5.0% away from that ceiling.
Are there dividends on Moderna shares?
Our data shows no dividend paid by Moderna over the trailing twelve months.
What is the analyst view on Moderna?
Of 13 analysts, 15% say buy, 62% hold and 23% sell. Price targets average $146.67, with the most cautious at $80.00 and the most optimistic at $260.00.
What does Moderna do?
Moderna develops vaccines and treatments based on mRNA technology, and became known for its COVID-19 vaccine.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MRNA.
Sign in to join the discussion.